Anti-Human MS4A1 Therapeutic Antibody (Obinutuzumab)
Recombinant Humanized (from mouse) antibody to Human MS4A1. Obinutuzumab was approved under the tradename obinutuzumab by the US FDA in 2013, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naive patients
| Supplier | Creative Biolabs |
|---|---|
| Product # | TAB-H51 |
| Pricing | Inquiry |
| Host | Mouse |
| Target | MS4A1 |
| Species Reactivity | Human |
| Type | IgG1 - kappa |
| Applications | FC, Inhib |